CA2804404C - Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury - Google Patents

Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury Download PDF

Info

Publication number
CA2804404C
CA2804404C CA2804404A CA2804404A CA2804404C CA 2804404 C CA2804404 C CA 2804404C CA 2804404 A CA2804404 A CA 2804404A CA 2804404 A CA2804404 A CA 2804404A CA 2804404 C CA2804404 C CA 2804404C
Authority
CA
Canada
Prior art keywords
arg
lys
phe
revascularization procedure
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2804404A
Other languages
English (en)
French (fr)
Other versions
CA2804404A1 (en
Inventor
Kenneth Borow
D. Travis Wilson
Robert A. Kloner
Sharon Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Good Samaritan Institute For Research And Education
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Corp
Good Samaritan Institute For Research And Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Corp, Good Samaritan Institute For Research And Education filed Critical Stealth Biotherapeutics Corp
Publication of CA2804404A1 publication Critical patent/CA2804404A1/en
Application granted granted Critical
Publication of CA2804404C publication Critical patent/CA2804404C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
CA2804404A 2010-07-09 2011-07-08 Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury Active CA2804404C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36313310P 2010-07-09 2010-07-09
US36312910P 2010-07-09 2010-07-09
US61/363,129 2010-07-09
US61/363,133 2010-07-09
US41265510P 2010-11-11 2010-11-11
US61/412,655 2010-11-11
PCT/US2011/043424 WO2012006569A1 (en) 2010-07-09 2011-07-08 Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury

Publications (2)

Publication Number Publication Date
CA2804404A1 CA2804404A1 (en) 2012-01-12
CA2804404C true CA2804404C (en) 2020-10-20

Family

ID=45441572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2804404A Active CA2804404C (en) 2010-07-09 2011-07-08 Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury

Country Status (7)

Country Link
US (2) US9345738B2 (cg-RX-API-DMAC7.html)
EP (3) EP4285994A3 (cg-RX-API-DMAC7.html)
JP (5) JP6319738B2 (cg-RX-API-DMAC7.html)
CN (4) CN103249423A (cg-RX-API-DMAC7.html)
CA (1) CA2804404C (cg-RX-API-DMAC7.html)
HK (1) HK1249428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012006569A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1204988A1 (en) * 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2869080C (en) * 2012-03-30 2020-09-01 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US11724030B2 (en) * 2018-09-21 2023-08-15 Corflow Therapeutics Ag Method and apparatus for diagnosis and treatment of microvascular dysfunction
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
AU2018336787B2 (en) 2017-09-19 2024-05-30 Corflow Therapeutics Ag Intracoronary characterization of microvascular obstruction (MVO) and myocardial infarction
IL305687B2 (en) * 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CN113544138B (zh) * 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
JPWO2020189593A1 (cg-RX-API-DMAC7.html) 2019-03-20 2020-09-24
RU2711414C1 (ru) * 2019-03-27 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ прогнозирования асимптомного повреждения вещества головного мозга при ангиореконструктивных операциях на сонных артериях
JP7638265B2 (ja) 2019-07-24 2025-03-03 ステルス バイオセラピューティクス インコーポレイテッド 神経変性疾患の治療におけるペプチド模倣化合物（ｒ）－２－アミノ－ｎ－（（ｓ）－ｌ－（（（ｓ）－５－アミノ－ｌ－（３－ベンジル－１，２，４－オキサジアゾール－５－イル）ペンチル）アミノ）－３－（４－ヒドロキシ－２，６－ジメチルフェニル）－ｉ－オキソプロパン－２－イル）－５－グアニジノペンタンアミド
EP4792852A2 (en) 2020-05-22 2026-08-19 CorFlow Therapeutics AG Controlled flow infusion microvascular dysfunction diagnostic and therapy
JP7533970B2 (ja) * 2022-01-31 2024-08-14 株式会社ニューギン 遊技機
JP7478453B2 (ja) * 2022-01-31 2024-05-07 株式会社ニューギン 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
JPH05301868A (ja) 1992-04-23 1993-11-16 Mitsui Toatsu Chem Inc 虚血性心疾患治療剤
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP1526140B1 (en) * 2002-08-01 2008-11-05 Astellas Pharma Inc. Potassium-dependent sodium-calcium exchanger
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Also Published As

Publication number Publication date
JP2016172781A (ja) 2016-09-29
US20130196921A1 (en) 2013-08-01
JP2013531682A (ja) 2013-08-08
CN105879008A (zh) 2016-08-24
EP2590664A4 (en) 2014-01-15
CN106620645A (zh) 2017-05-10
CA2804404A1 (en) 2012-01-12
EP2590664A1 (en) 2013-05-15
EP4285994A3 (en) 2024-01-17
JP2020114880A (ja) 2020-07-30
JP2019052188A (ja) 2019-04-04
US10322159B2 (en) 2019-06-18
EP2590664B1 (en) 2019-03-27
WO2012006569A1 (en) 2012-01-12
US9345738B2 (en) 2016-05-24
EP3539554A1 (en) 2019-09-18
JP6319738B2 (ja) 2018-05-09
JP2022012924A (ja) 2022-01-17
CN103249423A (zh) 2013-08-14
EP4285994A2 (en) 2023-12-06
HK1249428A1 (zh) 2018-11-02
CN107569675A (zh) 2018-01-12
US20170087204A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
US10322159B2 (en) Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20250262269A1 (en) Methods for performing a coronary artery bypass graft procedure
US20200223887A1 (en) Aromatic-cationic peptides and methods for using same
US20190336566A1 (en) Methods for the prevention or treatment of vessel occlusion injury
CA2916497C (en) Methods for the regulation of matrix metalloproteinase expression
WO2016004441A1 (en) Methods for the prevention or treatment of acute myocardial infarction injury
AU2019203050A1 (en) Methods for performing a coronary artery bypass graft procedure
HK1178086A (en) Methods for the prevention or treatment of vessel occlusion injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260706

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260706